Anticoagulation module 6: Peripheral arterial disease, cancer, thrombosis and anticoagulation requirements

Released27 October 2021     Expires: 27 October 2023      Programme: Anticoagulation 0.5 CPD/CME credits

Sponsorship Statement: This module and its 2021 revision has been funded by educational grants from Bayer. Bayer had no role in the writing of the modules and had no editorial control over the content.

Designed to give healthcare professionals a greater understanding of peripheral arterial disease, cancer, thrombosis and the requirements for anticoagulation.

Module first published: January 2019
First revision: 27th October 2021

Learning objectives

Upon completing this module, participants should be better able to:

  • identify peripheral arterial disease and its management
  • understand the risk factors for venous thromboembolism (VTE) and the management options with direct oral anticoagulants
  • know about the prevalence of undiagnosed cancer in patients with an unprovoked VTE and the management of cancer-associated thrombosis

Faculty

Dr Zara Sayar, Haematology Consultant, Whittington Health NHS Trust, London, and  University College Hospital, London
First revision (2021) by Dr Prabal Mittal, Haematology Clinical Research Fellow, University College London Hospitals NHS Foundation Trust, in association with Dr Zara Sayar

Accreditation

0.5 CPD/CME credit, 0.5 hour
BJC Learning has assigned half an hour of CPD/CME credit to this module

Endorsed by:

You need to login to take this module

You need to be a registered member to view this page. It's quick, free and offers you a host of other benefits, including the facility to print and download articles and supplements, access our archived issues and receive email updates when new issues and other content are online.

5 thoughts on “Anticoagulation module 6: Peripheral arterial disease, cancer, thrombosis and anticoagulation requirements”

All rights reserved. No part of this programme may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers, Medinews (Cardiology) Limited.

It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs becomes necessary. The editors/authors/contributors and the publishers have taken care to ensure that the information given in this text is accurate and up to date. Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice.

Healthcare professionals should consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.